Hemispherx Biopharma Stock Price - HEB

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last: $ 1.88 ▼ -0.01 (-0.53%)
Company Name Stock Ticker Symbol Market Type
Hemispherx Biopharma HEB AMEX Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.01 -0.53% 1.89 2.00 1.71 2.00 1.90 19:48:20
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
443 90,095 $ 1.81 $ 162,645 134,346 1.69 - 14.81
Last Trade Time Type Quantity Stock Price Currency
20:00:00 587 $ 1.89 USD

Hemispherx Biopharma Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 4.19M 2.22M $ -9.81M -9.68 - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
133.15k $ - 0.00% - -

more financials information »

Hemispherx Biopharma News

Loading Messages....

Latest HEB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HEB Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week2.192.271.691.923083k-0.3-13.70%
1 Month4.054.06041.692.3473146k-2.16-53.33%
3 Months6.2487.51.694.70311M-4.358-69.75%
6 Months10.1214.81041.697.30923M-8.23-81.32%
1 Year12.7614.81041.697.56111M-10.87-85.19%
3 Years89.76115.94881.6916.5901750k-87.87-97.89%
5 Years142.56211.21.6968.0048886k-140.67-98.67%

Hemispherx Biopharma Description

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.